Correction to An antisense oligonucleotide targeting the heat-shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis

IF 7.7 2区医学 Q1 PHARMACOLOGY & PHARMACY

British Journal of Pharmacology Pub Date : 2025-09-04 DOI:10.1111/bph.70197

{"title":"Correction to An antisense oligonucleotide targeting the heat-shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis","authors":"","doi":"10.1111/bph.70197","DOIUrl":null,"url":null,"abstract":"\n Boutanquoi, P.-M., Pommerolle, L., Dondaine, L., Tanguy, J., Bellaye, P.-S., Biziorek, L., Gautier-Isola, M., Mari, B., Masnikov, D., Rocchi, P., Finetti, P., Korczak, P., Vialet, B., Barthelemy, P., Garrido, C., Bonniaud, P., Burgy, O., and Goirand, F. An antisense oligonucleotide targeting the heat-shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis. British Journal of Pharmacology 182, no. 12 (2025): 2713–2729, https://doi.org/10.1111/bph.17470The published article's Conflict of Interest statement did not include one author's potential competing interest. The correct Conflict of Interest statement is as follows:CONFLICT OF INTEREST STATEMENTP. Rocchi is a cofounder of SilonTx (https://silontx.com), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics. The other authors declare no competing interests.We apologize for this error.","PeriodicalId":9262,"journal":{"name":"British Journal of Pharmacology","volume":"182 21","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bph.70197","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70197","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Boutanquoi, P.-M., Pommerolle, L., Dondaine, L., Tanguy, J., Bellaye, P.-S., Biziorek, L., Gautier-Isola, M., Mari, B., Masnikov, D., Rocchi, P., Finetti, P., Korczak, P., Vialet, B., Barthelemy, P., Garrido, C., Bonniaud, P., Burgy, O., and Goirand, F. An antisense oligonucleotide targeting the heat-shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis. British Journal of Pharmacology 182, no. 12 (2025): 2713–2729, https://doi.org/10.1111/bph.17470

The published article's Conflict of Interest statement did not include one author's potential competing interest. The correct Conflict of Interest statement is as follows:

CONFLICT OF INTEREST STATEMENT

P. Rocchi is a cofounder of SilonTx (https://silontx.com), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics. The other authors declare no competing interests.

We apologize for this error.

Abstract Image

查看原文本刊更多论文

针对热休克蛋白HSPB5的反义寡核苷酸作为肺纤维化的一种创新治疗方法。

Boutanquoi,下午。， L. Pommerolle， L. Dondaine， L. Tanguy， J., Bellaye， P.-S.。， Biziorek， L., Gautier-Isola， M., Mari， B., Masnikov， D., Rocchi， P., Finetti， P., Korczak， P., Vialet， B., Barthelemy， P., Garrido， C., Bonniaud， P., Burgy， O.和Goirand， F.一种针对热休克蛋白HSPB5的反义寡核苷酸作为肺纤维化的创新治疗方法。《英国药理学杂志》182，第2期。12 (2025): 2713-2729, https://doi.org/10.1111/bph.17470The发表的文章的利益冲突声明没有包括一个作者的潜在竞争利益。正确的利益冲突声明如下：利益冲突声明罗基是silonx （https://silontx.com）的联合创始人，silonx是一家生物技术公司，成立于2024年4月，专注于精准医学和核酸治疗。其他作者声明没有利益冲突。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Pharmacology 医学-药学

CiteScore

15.40

自引率

12.30%

发文量

270

审稿时长

2.0 months

期刊介绍： The British Journal of Pharmacology (BJP) is a biomedical science journal offering comprehensive international coverage of experimental and translational pharmacology. It publishes original research, authoritative reviews, mini reviews, systematic reviews, meta-analyses, databases, letters to the Editor, and commentaries. Review articles, databases, systematic reviews, and meta-analyses are typically commissioned, but unsolicited contributions are also considered, either as standalone papers or part of themed issues. In addition to basic science research, BJP features translational pharmacology research, including proof-of-concept and early mechanistic studies in humans. While it generally does not publish first-in-man phase I studies or phase IIb, III, or IV studies, exceptions may be made under certain circumstances, particularly if results are combined with preclinical studies.